Lightpoint Medical completed an $8 M financing round for commercial launch of its robotic probe
Lightpoint Medical raised $8 million to finance further clinical trials and commercialization of their SENSEI® robotic cancer probe. The technology received CE Mark approval in early 2021, as well as approval for sale in Australia,and has been registered with the FDA in the US.
SENSEI® is applicable across a wide range of major cancer types, including lung, colorectal, stomach, gynecological, and prostate cancer and has the potential to assist in over 2 million applicable surgical procedures every year in the EU, US, China and Japan.
Photo: Lightpoint Medical